Diligence memo · auto-generated · as of July 2, 2026
Neurawell Therapeutics, Inc.
Neurawell Therapeutics, Inc. looks under-valued against its niche peers and is quiet on financing cadence.
Businessfiled
Neurawell Therapeutics, Inc. operates in Pharma, based in SUNNY ISLES BEACH.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Neurawell Therapeutics, Inc. has raised $1.6M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $1.6M on 2024-05-20.
Most recent recorded round closed around 2024-05-20.
Valuation (modeled)modeled
Provath models Neurawell Therapeutics, Inc. at approximately $8.2M (range $1.2M–$22M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.60× the median modeled value of Seed Pharma companies in 2022–2024 (18 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 2.1 yr ago; this sector typically re-raises about every 16 months.
Slightly overdue versus sector cadence.
Comparablesmixed
Capital scale ranks ahead of 42% of Pharma peers (310 compared).
Modeled value ranks above 32% of those peers.
Closest niche peers: Seal Rock Therapeutics, Inc., Diligent Pharma, Inc., A28 Therapeutics, Inc., Centaurus Therapeutics, Inc., Pathfinder Oncology, Inc..
Peoplefiled
3 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.